Imagen de Portada
Código QR

Maximum Output Starts with Optimized Upstream Processing: Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics.

10 BioPharm International April 2021 www.biopharminternational.com Kuzmick/Stock.Adobe.com Maximum Output Starts with Optimized Upstream Processing Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics. Biopharmaceutical companies of all sizes have sought additio...

Descripción completa

Publicado en:BioPharm International Vol. 34; no. 4; pp. 10 - 16
Autor principal: CHALLENER, CYNTHIA A.
Formato: Journal Article
Publicado: MJH Life Sciences Apr2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149681355&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 149681355
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1542166X
        5NE
      jtl: BioPharm International
      issn: 1542166X
      maglogo: N
    pubinfo:
      dt: Apr2021
      vid: 34
      iid: 4
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        149681355
        149681355
      ppf: 10
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Maximum Output Starts with Optimized Upstream Processing: Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics.
      aug:
        au: CHALLENER, CYNTHIA A.
      sug:
      ab: 10 BioPharm International April 2021 www.biopharminternational.com Kuzmick/Stock.Adobe.com Maximum Output Starts with Optimized Upstream Processing Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics. Biopharmaceutical companies of all sizes have sought additional contract manufacturing capacity to free internal capacity, expedite process development and large-scale manufacture, and forge partnerships to secure secondary sources in their drug supply chains, according to Kim. That is at least true for large biopharmaceutical companies, but small and emerging biotech companies typically rely on the manufacturing capacity, expertise, and flexibility of CDMOs to bring their candidates to market.
      pubtype: Trade Publication
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N